TP53 and urinary bladder cancer: Fechner et al (2003) studied four different TCC cell lines (RT112, RT4, T24 and SUP) with differing p53 status and found that the addition of gemcitabine resulted in no radiosensitising effect. Another study (Pauwels et al, 2003) investigated a number of tumour cell types including an epidermioid bladder cancer cell line (ECV304) and found significant radiosensitising effects caused by gemcitabine.